Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Thiogenesis Therapeutics Corp.

Healthcare CA TTI

0.58CAD
-0.02(3.33%)

Last update at 2026-06-05T15:19:00Z

Day Range

0.580.60
LowHigh

52 Week Range

0.440.88
LowHigh

Fundamentals

  • Previous Close 0.60
  • Market Cap31.62M
  • Volume10716
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -3.14573M -5.06301M -3.92425M -0.22446M -0.09268M
Minority interest - - - - -
Net income -3.14573M -5.06301M -3.92425M -0.22446M -0.09268M
Selling general administrative 1.36M 1.04M 0.93M 0.22M 0.09M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - - - - -
Ebitda - - - -0.22443M -0.09265M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -3.57927M -5.20602M -1.97485M -0.22468M -0.09265M
Other operating expenses - - - - -
Interest expense - 0.00000M 0.00412M 0.00003M 0.00003M
Tax provision - - - - -
Interest income 0.20M 0.17M 0.00618M 0.00025M 0.00000M
Net interest income 0.20M 0.17M 0.00206M 0.00022M -0.00003M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 3.58M 5.21M 1.97M 0.22M 0.09M
Cost of revenue - - - - -
Total other income expense net 0.23M -0.02815M -1.95146M - -
Discontinued operations - - - - -
Net income from continuing ops -3.14573M -5.06301M -3.92425M -0.22446M -0.09268M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 3.98M 7.24M 6.29M 3.43M 0.15M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - -
Total liab 0.56M 1.71M 0.31M 3.49M 0.06M
Total stockholder equity 3.43M 5.53M 5.98M -0.06107M 0.08M
Deferred long term liab - - - - -
Other current liab - - - - -
Common stock - - - - -
Capital stock 16.14M 15.01M 11.13M 0.30M 0.27M
Retained earnings -14.28376M -11.13803M -6.17745M -0.45342M -0.22897M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 3.85M 7.08M 6.20M - 0.02M
Cash and equivalents - - - - -
Total current liabilities 0.56M 1.71M 0.31M 3.49M 0.06M
Current deferred revenue - - - - -
Net debt - - - - 0.30M
Short term debt - - - - -
Short long term debt - - - - 0.32M
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - - - - -
Total current assets 3.98M 7.24M 6.29M 3.43M 0.15M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 0.00261M 0.00600M 0.00732M - 0.00135M
Long term debt - - - - -
Inventory - - - - -
Accounts payable - - - - 0.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - 0.00000M 0.11M - -
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings - 0.00000M -0.17517M - -
Total cash from financing activities 0.72M 4.12M 8.13M 3.33M 0.00011M
Change to operating activities - - - - -
Net income -3.14573M -5.06301M -3.92425M -0.22446M -0.09268M
Change in cash -3.22844M 0.88M 6.13M 3.26M -0.03577M
Begin period cash flow 7.08M 6.20M 3.41M 0.15M 0.18M
End period cash flow 3.85M 7.08M 6.20M 3.41M 0.15M
Total cash from operating activities -3.92057M -3.24846M -2.08969M -0.06708M -0.03588M
Issuance of capital stock 0.00000M 4.12M 4.88M - 0.00000M
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.00261M -0.06407M -0.00799M - 0.00089M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - - -
Change to netincome - - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.12382M 1.33M -0.56881M 0.16M 0.06M
Stock based compensation 0.35M 0.48M 0.52M - 0.03M
Other non cash items - - 1.94M - 0.00351M
Free cash flow -3.92057M -3.24846M -2.08969M -0.06708M -0.03588M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
TTI
Thiogenesis Therapeutics Corp.		 -0.02 3.33% 0.58 - - - 15.17 -58.1577
SHRX
Sharp Therapeutics Corp.		 - -% 2.10 - - - 32.37
NRX
NurExone Biologic Inc.		 -0.01 1.69% 0.58 - 6.90 - 15.26 -7.2365
MIR
MedMira Inc		 0.005 9.09% 0.06 - - 223.37 - 293.42 -80.0318
ARCH
Arch Biopartners Inc		 -0.03 5.77% 0.49 - - 197.68 6211.54 53.05 6970.51

Reports Covered

Stock Research & News

View All

Profile

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.

Thiogenesis Therapeutics Corp.

4 King Street West, Toronto, ON, Canada, M5H 1B6

Key Executives

Name Title Year Born
Dr. Patrice P. Rioux M.D., Ph.D. CEO & Director 1951
Ms. Mary Jo Bagger Consultant for Clinical Operations NA
Mr. Brook G. Riggins C.F.A. CFO, Sec. & Director 1966
Dr. Patrice P. Rioux M.D., Ph.D. Co-Founder, CEO & Director 1951
Mr. Brook G. Riggins C.F.A. CFO, Secretary & Director 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.